TP53 and head and neck squamous cell carcinoma: For example, a Wilms Tumor 1 (WT1) peptide-pulsed DC vaccine, which targets a common WT1 gene mutation in HNSCC (114), and a p53 peptide-loaded DC vaccine, targeting the p53 gene (115), are already undergoing clinical trials and will be described in detail in the next section.